I. COMMENCED TRADING IN FEBRUARY

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out (M)@

Lead, Other
Underwriters

Gross
(M)

Post-
Offering
Market
Cap (M)%
INITIAL OFFERINGS

3SBIO Inc. (China;
SSRX)1

1/22/07

2/7/07

7.2S

$16

150.3

UBS Investment Bank, CIBC World Markets, Pacific Growth Equities

$115.2

$344.2

BioLineRx Ltd.
(Israel; TASE:BLRX)2

2/7/07

2/7/07

28.7S

$1.74

N/A

Clal Finance, Leader Capital Mark (co-lead)

$50

N/A

Cellectis SA
(France; Euronext)3

12/26/06

2/6/07

2.1S

€10.25

N/A

Societe Generale

€21.2 (US$27.5)

N/A

Molecular
Insight
Pharmaceuticals
Inc. (MIPI)4

11/8/05

2/2/07

5S

$14

24.7

RBC Capital Markets, Jefferies & Co. (co-lead), Oppenheimer & Co., AG Edwards

$70

$345.8

Optimer
Pharmaceuticals
Inc. (OPTR)5

11/9/06

2/9/07

7S

$7

21.7

Piper Jaffray & Co., Jefferies & Co. (co-lead), JMP Securities, Rodman & Renshaw

$49

$151.9

Rosetta
Genomics Ltd.
(Israel; ROSG)6

9/7/06

2/27/07

3.75S

$7

11.3

C.E. Unterberg, Towbin, Oppenheimer & Co.

$26.3

$79.1

Synta
Pharmaceuticals
Corp. (SNTA)7

11/22/06

2/6/07

5S

$10

33.8

Bear, Stearns & Co., Lehman Brothers (co-lead), Lazard Capital Markets, Montgomery & Co.

$50

$338
Total: $388.0M
Number of IPOs in February: 7
Average value of February IPOs: $55.43M
Number of IPOs in 2007: 7
Total raised in IPOs in 2007: $388.0M
Average value of IPOs in 2007: $55.43M
FOLLOW-ON OFFERINGS

BioMimetic
Therapeutics
Inc. (BMTI)8

2/9/07

2/9/07

2.52S

$17.15

17.8

Deutsche Bank Sec., Pacific Growth (co-lead), First Albany Capital, AG Edwards & Sons

$43.2

$305.3

Bruker
BioSciences
Corp. (BRKR)9

2/6/07

2/13/07

2.53S

$7.10

104.8

Bear Stearns & Co., UBS Investment Bank (co-lead)

$17.96

$744.1

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units
(M)

Price

Shares
Out (M)@

Lead, Other Underwriters

Gross (M)

Post- Offering
Market
Cap (M)%

Myriad Genetics
Inc. (MYGN)10

2/8/07

3S

$35.90

42.9

J.P. Morgan Securities

$107.7

$1.5B

Oncolytics
Biotech Inc.
(Canada; ONCY;
TSX:ONC)11

2/22/07

2/22/07

4U

C$3

36.5

Canaccord Capital Corp.

C$12
(US$10.3)

C$109.5
(US$93.4)

Palatin
Technologies
Inc. (AMEX:PTN)12

2/13/07

2/16/07

13.75S

$2

84.9

Pacific Growth Equities

$27.5

$169.8

SemBioSys
Genetics Inc.
(Canada; TSX:SBS)13

1/16/07

2/20/07

4.25S

C$3

N/A

Raymond James Ltd.

C$12.8
(US$10.9)

N/A

Theratechnologies
Inc. (Canada;
TSX:TH)14

2/20/07

2/27/07

6.875S

C$8.40

N/A

BMO Capital Markets,
Canaccord Capital,
National Bank Financial,
Desjardins Securities,
Jennings Capital

C$57.8
(US$49.8)

N/A
Total: $267.36M
Number of follow-on offerings in February: 7
Average value of February follow-ons: $38.19M
Number of follow-on offerings in 2007: 15
Total raised in follow-ons in 2007: $840.86M
Average value of follow-ons in 2007: $56.1M
Notes:
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
@ This column reflects the shares outstanding following the offering, when disclosed.
% Market capitalization is calculated based on the offering price.
Currency conversions are based on exchange rates at the time of the deal.
CDNX = Canadian Venture Exchange; SWX = Swiss Stock Exchange; TASE = Tel Aviv Stock Exchange.
1. 3SBIO's IPO involves 7.2M American Depositary shares, representing 50.3M ordinary shares. Company shareholders also offered 512,183 ADSs. Underwriters have a 30-day option to purchase up to 1.2M additional ADSs to cover any overallotments. The post-offering market cap was calculated using a per share price of $2.29, since each ADS equals approximately 7 ordinary shares.
2. BioLineRx's IPO on the Tel Aviv Stock Exchange included investments from Teva Pharmaceuticals Ltd., Pitango Venture Capital, Giza Venture Capital and Hadasit, the technology transfer arm of Hadasit University.
3. Cellectis' IPO on the Alternext market of the Paris Euronext stock exchange includes a 15 percent overallotment option.
4. Molecular Insight's underwriters have an overallotment option for 750,000 additional shares.
5. Optimer's IPO includes the exercise of an overallotment option for 1.1M shares that were purchased from Par Pharmaceuticals Companies Inc., which received the proceeds.
6. Rosetta's underwriters for the IPO have an overallotment option for another 562,500 shares.
7. Synta's underwriters have an overallotment option for 750,000 additional shares.
8. BioMimetic's offering includes the exercise of an overallotment option for 424,350 shares.
9. Bruker's offering included another 9.43M shares sold by four stockholders at the same price, as well as 1.56M shares total - 330,000 from the company and 1.23M from the stockholders - to cover overallotments.
10. Myriad's underwriter has an option to purchase up to 450,000 shares to cover overallotments.
11. Oncolytics' underwriter has an overallotment option for an additional 600,000 units. Each unit comprises one common share and one-half of one share purchase warrant.
12. Palatin's offering raised $27.5M gross. The company expected net proceeds of about $26M.
13. SemBioSys offered 7M shares, 4.25M from the company and the rest from shareholders.
14. Theratechnologies' offering includes the full exercise of an overallotment option for 625,000 shares.
II. FILED AND PENDING

Company
(Symbol/
Proposed
Symbol)#*

Date
Filed

Shares/
Units
(M)

Price
Range

Shares
Out
(M)@

Lead, Other
Underwriters

Value
(M)
INITIAL OFFERINGS

Biodel Inc.
(BIOD)1

2/7/07

N/A

N/A

N/A

Banc of America Securities, CIBC World Markets (co-lead), Leerink Swann & Co., Natexis Bleichroeder

$86.25

Bioheart Inc.
(BHRT)2

2/13/07

N/A

N/A

21.5

BMO Capital Markets Corp., Janney Montgomery Scott (co-lead), Merriman Curhan Ford & Co.

$35

Cosmo
Pharmaceuticals
SpA (Italy; SSE)3

2/27/07

3.42S

CHF22 to CHF28

N/A

Lehman Brothers International, Sal. Oppenheim Jr. & Cie (co-lead)

CHF321.6- CHF409.3

EndoCeutics
Inc. (Canada;
ENCX)4

2/27/07

N/A

N/A

N/A

First Albany Capital, Oppenheimer & Co., Stifel Nicolaus

$75

Light Sciences
Oncology Inc.
(LSON)5

4/21/06

5.25S

$14-$16

18.5

Cowen & Co., Wachovia Securities (co-lead), Jefferies & Co., Thomas Weisel Partners

$78.75

NeurogesX Inc.
(NGSX)6

2/8/07

N/A

N/A

N/A

Morgan Stanely, Pacific Growth Equities, Lazard Capital Markets, Susquehanna Financial

$69

NovaBay
Pharmaceuticals
Inc.
(AMEX:NBY;
TSX:NBY)7

2/15/07

N/A

N/A

31.8

N/A

$23

OncoGenex
Technologies
Inc. (Canada;
OGXI;
TSX:OGX)8

12/13/06

5S

$7.50 - $8.50

16.1

RBC Capital Markets, Needham & Co., Lazard Capital Markets, Canaccord Adams, Susquehanna Financial Group

$40

Orexigen
Therapeutics
Inc. (OREX)9

12/16/06

N/A

N/A

N/A

Merrill Lynch & Co., JP Morgan Securities (co-lead), JMP Securities, Leerink Swann & Co.

$86.25

Perlegen
Sciences Inc.
(PERL)10

4/10/06

N/A

N/A

N/A

Lehman Brothers, Deutsche Bank Securities (co-lead), Piper Jaffray & Co., Allen & Co.

$115

Pharmasset
Inc. (VRUS)11

5/9/06

N/A

N/A

N/A

Banc of America Securities, UBS Investment Bank (co-lead), JMP Securities

$75

PTC
Therapeutics
Inc. (PTCT)12

3/31/06

N/A

N/A

N/A

Morgan Stanley & Co., JP Morgan Securities (co-lead), Pacific Growth Equities

$86.25

Sucampo
Pharmaceuticals
Inc. (SCMP)13

6/19/06

N/A

N/A

N/A

Banc of America Securities, Deutsche Bank Securities (co-lead) Leerink Swann & Co.

$86.25
FOLLOW-ON OFFERINGS

Neurochem Inc.
(NRMX)14

1/18/07

NA

NA

N/A

N/A

$102
Notes:
# Unless otherwise indicated, shares are traded on the Nasdaq exchange; general shelf registration statements are not included until action is taken on the filing.
* Stock symbols for companies seeking to complete IPOs are proposed.
@ This column reflects the shares outstanding following the offering, when disclosed.
N/A = Not available, applicable or reported.
TSX = Toronto Stock Exchange.
1. Biodel filed to raise $86.25M in its IPO.
2. Bioheart filed for a $35M IPO.
3. Cosmo's IPO includes an overallotment option for an additional 512,870 shares.
4. EndoCeutics did not disclose the number of shares to be offered in its IPO or the price range.
5. Light Sciences Oncology filed to raise up to $86.25M in an IPO. The shares and price range were estimated in September. The value is based on the midpoint of those estimates.
6. NeurogesX filed to raise $69M in its IPO. The number of shares and price range were not disclosed.
7. NovaBay is seeking a dual listing on the American and Toronto stock exchanges, hoping to raise $23M.
8. OncoGenex's IPO value reflects 5M shares sold at $8 each, the midpoint of the price range. The underwriters have an overallotment option for 750,000 shares.
9. Orexigen filed to raise up to $86.25M in an IPO.
10. Perlegen filed to raise up to $115M in an IPO.
11. Pharmasset filed to raise up to $75M in an IPO.
12. PTC Therapeutics filed to raise up to $86.25M in an IPO.
13. Sucampo filed to raise up to $86.25M in an IPO.
14. Neurochem filed registration statements for $102M in Canada and the U.S. including the resale of up to $60M of its common shares and the resale of 6% senior convertible notes.